FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012621808> ?p ?o ?g. }

• W2012621808 endingPage "335" @default.
• W2012621808 startingPage "329" @default.
• W2012621808 abstract "A successful vaccine development strategy for areas with clustered H5N1 events requires conduct of vaccine trials in potentially non-naïve subjects and evaluation of post-vaccination responsiveness. An open-label, randomized, phase I/II study therefore assessed the immunogenicity and safety of two different dose levels of an inactivated, non-adjuvanted, whole virus clade 2.1 (A/Indonesia/05/2005) H5N1 Vero cell-derived influenza vaccine in healthy adults (21–45 years) from a region where the virus has been circulating (Hong Kong) as well as Singapore. Subjects (N = 110) were randomized 1:1 to receive two vaccinations with either 3.75 μg or 7.5 μg H5N1 haemagglutinin antigen 21 days apart. Safety, immunogenicity (microneutralization [MN] and single radial haemolysis [SRH] at baseline and post-vaccination) and cross-reactivity against a heterologous clade 1 strain (A/Vietnam/1203/2004) of the vaccine were assessed. Pre-existing immunity to the vaccine strain was 14% which is higher than previously reported for these regions. Two vaccinations with either vaccine formulation induced high seroprotection rates (MN titre ≥ 1:20) against the vaccine strain A/Indonesia/05/2005: 82.7% and 86.5% in the 3.75 μg and 7.5 μg dose groups. Seroconversion rates and fold increase exceeded the CPMP criterion of >40% and >2.5 for MN and SRH in both dose groups after the second vaccination, while the seroprotection rate in the 7.5 μg dose group determined by SRH was only marginally lower (69.2%) than the CPMP criterion of >70%. Thus, 11 of 12 CHMP criteria were fulfilled. A cross-reactive antibody response against the heterologous A/Vietnam/1203/2004 strain was demonstrated after the second vaccination (>21% by MN and ≥25% by SRH). Persistence of antibodies against the vaccine strain was also demonstrated 6 months after the first vaccination, indicating that a booster vaccination would be effective in those who have received two priming doses. No serious adverse events were reported. The H5N1 influenza vaccine against clade 2.1 strain A/Indonesia/05/2005 was well tolerated and immunogenic after two vaccinations, and induced a cross-neutralizing antibody response, with no dose effect." @default.
• W2012621808 created "2016-06-24" @default.
• W2012621808 creator A5000220054 @default.
• W2012621808 creator A5005000822 @default.
• W2012621808 creator A5013621761 @default.
• W2012621808 creator A5037393708 @default.
• W2012621808 creator A5040252912 @default.
• W2012621808 creator A5040527713 @default.
• W2012621808 creator A5043918234 @default.
• W2012621808 creator A5045211170 @default.
• W2012621808 creator A5058132783 @default.
• W2012621808 creator A5074280752 @default.
• W2012621808 creator A5074675036 @default.
• W2012621808 creator A5083013117 @default.
• W2012621808 creator A5083717158 @default.
• W2012621808 creator A5089024033 @default.
• W2012621808 date "2012-01-01" @default.
• W2012621808 modified "2023-09-30" @default.
• W2012621808 title "Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine" @default.
• W2012621808 cites W1487246189 @default.
• W2012621808 cites W1909806257 @default.
• W2012621808 cites W1973918707 @default.
• W2012621808 cites W1982019229 @default.
• W2012621808 cites W1984429318 @default.
• W2012621808 cites W1985582011 @default.
• W2012621808 cites W1993391185 @default.
• W2012621808 cites W1999942453 @default.
• W2012621808 cites W2008610318 @default.
• W2012621808 cites W2011879952 @default.
• W2012621808 cites W2011983340 @default.
• W2012621808 cites W2017076506 @default.
• W2012621808 cites W2018151048 @default.
• W2012621808 cites W2019850722 @default.
• W2012621808 cites W2043491965 @default.
• W2012621808 cites W2065069831 @default.
• W2012621808 cites W2069699462 @default.
• W2012621808 cites W2071009174 @default.
• W2012621808 cites W2087508560 @default.
• W2012621808 cites W2102603483 @default.
• W2012621808 cites W2119671142 @default.
• W2012621808 cites W2121758361 @default.
• W2012621808 cites W2131170401 @default.
• W2012621808 cites W2132848815 @default.
• W2012621808 cites W2157384064 @default.
• W2012621808 cites W2164684229 @default.
• W2012621808 doi "https://doi.org/10.1016/j.vaccine.2011.10.088" @default.
• W2012621808 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22080174" @default.
• W2012621808 hasPublicationYear "2012" @default.
• W2012621808 type Work @default.
• W2012621808 sameAs 2012621808 @default.
• W2012621808 citedByCount "24" @default.
• W2012621808 countsByYear W20126218082012 @default.
• W2012621808 countsByYear W20126218082013 @default.
• W2012621808 countsByYear W20126218082014 @default.
• W2012621808 countsByYear W20126218082015 @default.
• W2012621808 countsByYear W20126218082016 @default.
• W2012621808 countsByYear W20126218082020 @default.
• W2012621808 countsByYear W20126218082021 @default.
• W2012621808 crossrefType "journal-article" @default.
• W2012621808 hasAuthorship W2012621808A5000220054 @default.
• W2012621808 hasAuthorship W2012621808A5005000822 @default.
• W2012621808 hasAuthorship W2012621808A5013621761 @default.
• W2012621808 hasAuthorship W2012621808A5037393708 @default.
• W2012621808 hasAuthorship W2012621808A5040252912 @default.
• W2012621808 hasAuthorship W2012621808A5040527713 @default.
• W2012621808 hasAuthorship W2012621808A5043918234 @default.
• W2012621808 hasAuthorship W2012621808A5045211170 @default.
• W2012621808 hasAuthorship W2012621808A5058132783 @default.
• W2012621808 hasAuthorship W2012621808A5074280752 @default.
• W2012621808 hasAuthorship W2012621808A5074675036 @default.
• W2012621808 hasAuthorship W2012621808A5083013117 @default.
• W2012621808 hasAuthorship W2012621808A5083717158 @default.
• W2012621808 hasAuthorship W2012621808A5089024033 @default.
• W2012621808 hasConcept C133239900 @default.
• W2012621808 hasConcept C147483822 @default.
• W2012621808 hasConcept C159047783 @default.
• W2012621808 hasConcept C203014093 @default.
• W2012621808 hasConcept C22070199 @default.
• W2012621808 hasConcept C2522874641 @default.
• W2012621808 hasConcept C2777451964 @default.
• W2012621808 hasConcept C2780689484 @default.
• W2012621808 hasConcept C2780868878 @default.
• W2012621808 hasConcept C519248777 @default.
• W2012621808 hasConcept C71924100 @default.
• W2012621808 hasConcept C89138240 @default.
• W2012621808 hasConceptScore W2012621808C133239900 @default.
• W2012621808 hasConceptScore W2012621808C147483822 @default.
• W2012621808 hasConceptScore W2012621808C159047783 @default.
• W2012621808 hasConceptScore W2012621808C203014093 @default.
• W2012621808 hasConceptScore W2012621808C22070199 @default.
• W2012621808 hasConceptScore W2012621808C2522874641 @default.
• W2012621808 hasConceptScore W2012621808C2777451964 @default.
• W2012621808 hasConceptScore W2012621808C2780689484 @default.
• W2012621808 hasConceptScore W2012621808C2780868878 @default.
• W2012621808 hasConceptScore W2012621808C519248777 @default.
• W2012621808 hasConceptScore W2012621808C71924100 @default.
• W2012621808 hasConceptScore W2012621808C89138240 @default.
• W2012621808 hasIssue "2" @default.

• next